术前使用维得利珠单抗治疗的炎症性肠病患者术后并发症风险
这项回顾性队列研究纳入443例在手术前4周内接受维得利珠单抗、抗肿瘤坏死因子-α(抗TNF-α)药物或非生物制剂治疗的溃疡性结肠炎(UC)和克罗恩病(CD)患者,比较各组30天术后并发症发生率。多因素分析显示年龄>65岁和低白蛋白与30天术后并发症风险升高相关;倾向性评分匹配分析显示三组并发症风险无差异(UC P=0.40;CD P=0.35)。作者认为术前维得利珠单抗暴露未影响30天术后并发症风险,但需更大规模研究证实。
要点
- 443例患者中144例(32%)发生术后并发症。
- 年龄>65岁(OR 3.56,95%CI 1.30-9.76)和低白蛋白(OR 2.26,95%CI 1.28-4.00)与30天术后并发症风险升高相关。
- 倾向性评分匹配后,维得利珠单抗、抗TNF-α药物与非生物制剂组术后并发症风险无差异(UC P=0.40;CD P=0.35)。
核心结论
- 本研究中术前维得利珠单抗暴露未影响UC和CD患者30天术后并发症风险,但需更大规模研究证实。
研究设计与样本
- 回顾性研究队列,纳入手术前4周内接受维得利珠单抗、抗TNF-α药物或非生物制剂治疗的患者443例(维得利珠单抗64例、抗TNF-α药物129例、非生物制剂250例)。
- 采用单因素和多因素分析比较组间30天术后并发症发生率,并进行倾向性评分匹配分析比较组间结局。
主要发现
- 443例患者中144例发生术后并发症(32%)。
- 多因素分析中,年龄>65岁(OR 3.56,95%CI 1.30-9.76)和低白蛋白(OR 2.26,95%CI 1.28-4.00)与30天术后并发症风险升高相关。
- 感染性并发症的多因素分析中,使用类固醇(OR 3.67,95%CI 1.57-8.57,P=0.003)和低血红蛋白(OR 3.03,95%CI 1.32-6.96,P=0.009)与风险升高相关。
- 倾向性评分匹配分析显示,术前接受维得利珠单抗、抗TNF-α药物或非生物制剂治疗的患者术后并发症风险无差异(UC P=0.40;CD P=0.35)。
关键数值与推荐
- 30天术后并发症总发生率为32%(144/443)。
- 年龄>65岁与30天术后并发症风险升高相关(OR 3.56,95%CI 1.30-9.76)。
- 低白蛋白与30天术后并发症风险升高相关(OR 2.26,95%CI 1.28-4.00)。
- 使用类固醇与感染性并发症风险升高相关(OR 3.67,95%CI 1.57-8.57,P=0.003)。
- 低血红蛋白与感染性并发症风险升高相关(OR 3.03,95%CI 1.32-6.96,P=0.009)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文结论指出需更大规模研究证实本研究结果。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: Vedolizumab is increasingly used to treat patients with ulcerative colitis (UC) and Crohn's disease (CD), however, its safety during the perioperative period remains unclear. We compared the 30-day postoperative complications among patients treated preoperatively with vedolizumab, anti-tumor necrosis factor (TNF)-α agents or non-biological therapy. METHODS: The retrospective study cohort was comprised of patients receiving vedolizumab, anti-TNF-α agents or non-biological therapy within 4 weeks of surgery. The rates of 30-day postoperative complications were compared between groups using univariate and multivariate analysis. Propensity score-matched analysis was performed to compare the outcome between groups. RESULTS: Among 443 patients (64 vedolizumab, 129 anti-TNF-α agents, and 250 non-biological therapy), a total of 144 patients experienced postoperative complications (32%). In multivariate analysis, age >65 (odds ratio (OR) 3.56, 95% confidence interval (CI) 1.30-9.76) and low-albumin (OR 2.26, 95% CI 1.28-4.00) were associated with increased risk of 30-day postoperative complications. For infectious complications, steroid use (OR 3.67, 95% CI 1.57-8.57, P=0.003) and low hemoglobin (OR 3.03, 95% CI 1.32-6.96, P=0.009) were associated with increased risk in multivariate analysis. Propensity score matched analysis demonstrated that the risks of postoperative complications were not different among patients preoperatively receiving vedolizumab, anti-TNF-α agents or non-biological therapy (UC, P=0.40; CD, P=0.35). CONCLUSIONS: In the present study, preoperative vedolizumab exposure did not affect the risk of 30-day postoperative complications in UC and CD. Further, larger studies are required to confirm our findings.
引用
- Yamada A, Komaki Y, Patel N, et al. Risk of Postoperative Complications Among Inflammatory Bowel Disease Patients Treated Preoperatively With Vedolizumab. Am J Gastroenterol. 2017. PMID: 28719595. doi:10.1038/ajg.2017.201
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。